Bli medlem
Bli medlem

Du är här

2016-04-11

Medivir: New data for simeprevir will be presented at EASL's International Liver Congress 2016

Press release, 11 April 2016

Stockholm, Sweden - Medivir AB (Nasdaq Stockholm: MVIR) today informs
that new clinical data for simeprevir, an NS3 / 4A protease inhibitor
for the treatment of hepatitis C virus infection, will be presented
by our partner Janssen Sciences Ireland UC (Janssen) in conjunction
with The International Liver Congress ™ 2016 of the European
Association for the Study of the Liver (EASL) in Barcelona, on 13-17
April. A total of nine presentations will be made, including one
"late breaker" presentation. The presentations will cover the
efficacy, safety and tolerability of simeprevir used as a component
of various combination therapies in a number of different adult
patient populations, and will be based on data from phase II and
phase III studies and from on-going clinical use (so-called
"real-world data").

Data presented at the International Liver Congress 2015 include:

Late-Breaking Poster Presentation

Simeprevir plus sofosbuvir for hepatitis C virus genotype 4 infection:
a phase 3, open-label study.

· Abstract LBP516
· Lead Author: M. Buti; Hospital Vall d'Hebron and Centro
Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas
(CIBERehd), Barcelona, Spain

Poster Presentations

Pharmacokinetic interactions between simeprevir and ledipasvir in
treatment-naïve hepatitis C virus genotype 1-infected patients
without cirrhosis treated with a simeprevir/sofosbuvir/ledipasvir
regimen

· Abstract SAT-264
· Lead Author: S. Bourgeois, Department of Internal Medicine, ZNA
Ster, Antwerp

Deep sequencing results from the Phase 2 IMPACT study of simeprevir in
combination with daclatasvir and sofosbuvir in treatment-naïve and
-experienced patients with chronic hepatitis C virus genotype 1 or 4
infection and decompensated liver disease

· Abstract THU-215
· Lead Author: C. Sarrazin, Johann Wolfgang Goethe University
Medical Center, Frankfurt am Main, Germany

Consistent simeprevir resistance profile in hepatitis C virus genotype
1-infected patients failing simeprevir interferon-free compared with
interferon-containing regimens

· Abstract THU-214
· Lead Author: B. Fevery, Janssen Infectious Diseases BVBA, Beerse,
Belgium

Effectiveness of simeprevir-containing regimens among patients with
chronic hepatitis C virus in various US practice settings: The SONET
study

· Abstract SAT-167
· Lead Author: I. Alam, Austin Hepatitis Center, Austin, TX, USA

Efficacy and safety of simeprevir and sofosbuvir with and without
ribavirin for 12 weeks in subjects with recurrent genotype 1
hepatitis C post-orthotopic liver transplant: The GALAXY study

· Abstract FRI-457
· Lead Author: J.G. O'Leary, Baylor University Medical Center,
Dallas, TX, USA

Efficacy and tolerability of simeprevir and daclatasvir for 12 or 24
weeks in HCV genotype 1b-infected treatment-naïve patients with
advanced fibrosis or compensated cirrhosis

· Abstract SAT-130
· Lead Author: C. Hézode, Department of Hepatology and
Gastroenterology, Hôpital Henri Mondor, Université Paris-Est, France

Effectiveness of simeprevir treatment for hepatitis C in real
practice: preliminary results from the STIly Italian observational
study

· Abstract SAT-162
· Lead Author: G.B. Gaeta, Seconda Universita di Napoli, Napoli,
Italy

Safety of simeprevir-based treatment for hepatitis C in real practice:
preliminary results from the STIly observational study

· Abstract SAT-212
· Lead Author: M. Colombo, Ospedale Maggiore Policlinico, Milano,
Italy

Details of all presentations for The International Liver Congress ™
2016 are available at the conference website:
http://www.ilc-congress.eu

For more information please contact:
Ola Burmark, CFO Medivir AB, mobile: +46 (0) 725 480 580.
Medivir is required under the Securities Markets Act to make the
information in this press release public.

The information was submitted for publication at 15.30 CET on 11 April
2016.

About Medivir
Medivir is a research based pharmaceutical company with a research
focus on oncology and infectious diseases. We have a leading
competence within protease inhibitor design and nucleotide/nucleoside
science and we are dedicated to develop innovative pharmaceuticals
that meet great unmet medical need. Our commercial organization
provides a portfolio of specialty care pharmaceuticals on the Nordic
market.

Medivir is listed on the Nasdaq Stockholm Mid Cap List.
-----------------------------------------------------------
http://news.cision.com/medivir/r/new-data-for-simeprevir-will-be-present...
http://mb.cision.com/Main/652/9953241/499291.pdf

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.